Back to Search
Start Over
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
- Source :
- Hematological Oncology, Cuneo, A, Barosi, G, Danesi, R, Fagiuoli, S, Ghia, P, Marzano, A, Montillo, M, Poletti, V, Viale, P & Zinzani, P L 2019, ' Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma : A multidisciplinary position paper ', Hematological Oncology, vol. 37, no. 1, pp. 3-14 . https://doi.org/10.1002/hon.2540
- Publication Year :
- 2019
-
Abstract
- The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL. The present publication represents a consensus document from a series of meetings held during 2017. The Panel generated clinical key questions using the criterion of clinical relevance through a Delphi process and explored 4 domains, ie, diarrhea/colitis, transaminitis, pneumonitis, and infectious complications. Using the consensus method, the Panel was able to shape recommendations which may assist hematologist to minimize adverse events and guarantee adherence to treatment in patients with CLL and FL candidate to receive idelalisib.
- Subjects :
- Oncology
Cancer Research
Adverse events
chronic lymphocytic leukemia
follicular lymphoma
idelalisib
Chronic lymphocytic leukemia
adverse event
Follicular lymphoma
Review
Antineoplastic Agent
0302 clinical medicine
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Cytochrome P-450 CYP3A
Drug Interactions
Disease management (health)
Lymphoma, Follicular
Disease Management
Hematology
General Medicine
Colitis
Algorithm
Aldehyde Oxidase
Drug Interaction
030220 oncology & carcinogenesis
Idelalisib
Algorithms
Human
Diarrhea
medicine.medical_specialty
Reviews
Antineoplastic Agents
Quinazolinone
NO
03 medical and health sciences
Internal medicine
medicine
Animals
Humans
Clinical significance
Adverse effect
Purine
Quinazolinones
Pneumonitis
adverse events
Antineoplastic Combined Chemotherapy Protocol
Animal
business.industry
medicine.disease
Leukemia, Lymphocytic, Chronic, B-Cell
Purines
Position paper
business
Coliti
030215 immunology
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Hematological Oncology, Cuneo, A, Barosi, G, Danesi, R, Fagiuoli, S, Ghia, P, Marzano, A, Montillo, M, Poletti, V, Viale, P & Zinzani, P L 2019, ' Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma : A multidisciplinary position paper ', Hematological Oncology, vol. 37, no. 1, pp. 3-14 . https://doi.org/10.1002/hon.2540
- Accession number :
- edsair.doi.dedup.....478c7cef8f06581cf5d7eb7d7ca2242d